• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Pharming Group N.V. ADS each representing 10

    4/7/25 4:04:55 PM ET
    $PHAR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PHAR alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Pharming Group N.V.

    (Name of Issuer)


    Ordinary Shares / American Depositary Shares

    (Title of Class of Securities)


    71716E105

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    71716E105


    1Names of Reporting Persons

    Morgan Stanley
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    8,446,801.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    8,471,801.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    8,471,801.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.2 %
    12Type of Reporting Person (See Instructions)

    HC, CO

    Comment for Type of Reporting Person:  As of the date hereof, Morgan Stanley has ceased to be the beneficial owner of more than five percent of the class of securities.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Pharming Group N.V.
    (b)Address of issuer's principal executive offices:

    DARWINWEG 24, LEIDEN, P7, 2333
    Item 2. 
    (a)Name of person filing:

    Morgan Stanley
    (b)Address or principal business office or, if none, residence:

    1585 Broadway, New York, NY 10036
    (c)Citizenship:

    Delaware
    (d)Title of class of securities:

    Ordinary Shares / American Depositary Shares
    (e)CUSIP No.:

    71716E105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See the response(s) to Item 9 on the attached cover page(s).
    (b)Percent of class:

    1.2  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See the response(s) to Item 5 on the attached cover page(s).

     (ii) Shared power to vote or to direct the vote:

    See the response(s) to Item 6 on the attached cover page(s).

     (iii) Sole power to dispose or to direct the disposition of:

    See the response(s) to Item 7 on the attached cover page(s).

     (iv) Shared power to dispose or to direct the disposition of:

    See the response(s) to Item 8 on the attached cover page(s).

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. * In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Morgan Stanley
     
    Signature:Christopher O'Hara
    Name/Title:Authorized Signatory, Morgan Stanley
    Date:04/07/2025
    Get the next $PHAR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PHAR

    DatePrice TargetRatingAnalyst
    12/9/2024$14.00Buy
    Jefferies
    More analyst ratings

    $PHAR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Pharming Group N.V. with a new price target

    Jefferies initiated coverage of Pharming Group N.V. with a rating of Buy and set a new price target of $14.00

    12/9/24 8:05:53 AM ET
    $PHAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHAR
    SEC Filings

    View All

    SEC Form 6-K filed by Pharming Group N.V. ADS each representing 10

    6-K - Pharming Group N.V. (0001828316) (Filer)

    2/3/26 6:37:56 AM ET
    $PHAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Pharming Group N.V. ADS each representing 10

    6-K - Pharming Group N.V. (0001828316) (Filer)

    2/2/26 7:21:09 AM ET
    $PHAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Pharming Group N.V. ADS each representing 10

    6-K - Pharming Group N.V. (0001828316) (Filer)

    1/8/26 6:29:45 AM ET
    $PHAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHAR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day

    Highlights advancing clinical-stage pipeline, including two major value-creating programs for primary immunodeficiencies (PIDs) with immune dysregulation and mtDNA-driven mitochondrial diseaseIntroduces napazimone (KL1333) as the compound name for the mtDNA-driven mitochondrial disease program2026 total revenue guidance of US$405 – US$425 million (8% to 13% growth)2026 total operating expense guidance of US$330 – US$335 millionInvestor Day will be webcast today starting at 10:00 am EST (16:00 CET) Leiden, The Netherlands, February 3, 2026: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) today announced 2026 financial guidance and will highlight its advancing clinical-stage r

    2/3/26 1:00:00 AM ET
    $PHAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja® (leniolisib) in children aged 4 to 11 years with APDS

    Leiden, the Netherlands, February 1, 2026: Pharming Group ((Euronext: PHARM, NASDAQ:PHAR) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to its supplemental New Drug Application (sNDA) for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency. The FDA raised an issue with the potential for underexposure in lower weight pediatric patients. As a result, the FDA has requested additional pediatric pharmacokinetic data to reassess the proposed pediatric dos

    2/1/26 3:17:00 PM ET
    $PHAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pharming Group reports preliminary 2025 revenues and announces Investor Day

    Leiden, The Netherlands, January 8, 2026: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) today announced its preliminary, unaudited revenues for the full year 2025 and plans to host a virtual Investor Day on February 3, 2026, at 10:00 am EST (16:00 CET). Total 2025 revenues are estimated to be approximately US$376 million*, exceeding the upwardly revised guidance range of US$365 to US$375 million provided in November 2025 and representing approximately 27% growth versus 2024. This strong performance reflects continued growth of RUCONEST® and rising demand for Joenja®, driven primarily by patient uptake in the U.S. and supported by ongoing geographic expansion. Full-year 202

    1/8/26 1:00:00 AM ET
    $PHAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHAR
    Leadership Updates

    Live Leadership Updates

    View All

    Pharming Group appoints Kenneth Lynard as Chief Financial Officer

    Leiden, the Netherlands, September 2, 2025: Pharming Group N.V. ("Pharming" or "the Company") ((Euronext: PHARM, NASDAQ:PHAR) today announced the appointment of Kenneth Lynard as Chief Financial Officer (CFO), effective October 1, 2025. Mr. Lynard is a seasoned finance executive with over 20 years of global leadership experience in the life sciences industry, recognized for driving financial and operational transformation across complex, multinational organizations. His appointment follows our strong first half 2025 financial results and marks an important step in strengthening our financial leadership as we continue to execute on our growth strategy. Fabrice Chouraqui, Chief Executive Of

    9/2/25 1:00:00 AM ET
    $PHAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders

    Leiden, the Netherlands, March 4, 2025: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM agenda. Shareholders approved the appointment of Mr. Fabrice Chouraqui as Executive Director and Chief Executive Officer for a term of four years. As a result, Mr. Chouraqui succeeds Mr. Sijmen de Vries with immediate effect. To ensure a smooth hand-over of tasks and responsibilities, Mr. de Vries will remain a strategic advisor to the new CEO until December 31, 2025. In addition, shareholders also approved the proposal to approve certain components of the remuneration pac

    3/4/25 9:15:00 AM ET
    $PHAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer

    Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces today that the Board of Directors has nominated Fabrice Chouraqui to become Pharming's new Executive Director and Chief Executive Officer, succeeding Sijmen de Vries. Pharming will nominate Mr. Chouraqui for the appointment as Executive Director and Chief Executive Officer for a term of four years at an upcoming Extraordinary General Meeting of Shareholders (EGM). Information regarding the EGM, including the notice to convene, will be shared shortly in a separate press release. Upon the appointment of Mr. Chouraqui, Sijmen de Vries will resign from the Board of Directors.

    1/21/25 1:00:00 AM ET
    $PHAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHAR
    Financials

    Live finance-specific insights

    View All

    Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow

    Total third quarter 2025 revenues increased by 30% to US$97.3 million, compared to third quarter 2024RUCONEST® third quarter revenue increased by 29% to US$82.2 million, compared to third quarter 2024, reflecting sustained growth in patients and prescribersJoenja® (leniolisib) third quarter revenue increased by 35% to US$15.1 million, compared to third quarter 2024, reflecting strong growth in patients on therapy FDA granted priority review of sNDA for leniolisib for children aged 4 to 11 years with APDS with decision expected by January 2026Third quarter operating profit increased by 285% to US$15.8 million, compared to US$4.1 million in the third quarter 2024Generated US$32.0 million in ca

    11/6/25 1:00:00 AM ET
    $PHAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pharming Group to report third quarter 2025 financial results and provide business update on November 6

    Leiden, the Netherlands, October 23, 2025: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) confirms that it will report its preliminary (unaudited) financial results for the third quarter 2025 and provide a business update on Thursday, November 6, 2025. Management will host a conference call and webcast for analysts and investors on the same day at 13:30 CET/07:30 am ET. To participate in the conference call or to watch the live webcast, please register in advance using the links below. Conference call registration:https://register-conf.media-server.com/register/BI1b6a1a63294c427f91ab7b24a7c6484b Once registered, dial-in information and a unique PIN will be provided, allowing access to

    10/23/25 2:00:08 AM ET
    $PHAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pharming Group reports second quarter and first half 2025 financial results and provides business update

    Second quarter 2025 total revenues increased by 26% to US$93.2 million, compared to the second quarter 2024, driven by strong RUCONEST® and Joenja® revenue growthRUCONEST® second quarter revenue increased by 28% to US$80.4 million, compared to the second quarter 2024, reflecting strong growth in patients and prescribersJoenja® (leniolisib) second quarter revenue increased by 15% to US$12.8 million, compared to the second quarter 2024, with a further acceleration in patient uptakeSecond quarter operating profit amounted to US$10.8 million compared to a US$3.1 million loss in the second quarter 2024Study published in leading peer-reviewed journal Cell identifies new variants leading to PI3Kδ p

    7/31/25 1:00:00 AM ET
    $PHAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHAR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Pharming Group N.V. ADS each representing 10

    SC 13G/A - Pharming Group N.V. (0001828316) (Subject)

    11/14/24 6:17:36 AM ET
    $PHAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Pharming Group N.V. ADS each representing 10

    SC 13G - Pharming Group N.V. (0001828316) (Subject)

    11/8/24 3:03:47 PM ET
    $PHAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Pharming Group N.V. ADS each representing 10

    SC 13G - Pharming Group N.V. (0001828316) (Subject)

    2/14/24 7:03:30 AM ET
    $PHAR
    Biotechnology: Pharmaceutical Preparations
    Health Care